On June 19-21, the 21st CPHI China 2023 was successfully held in Shanghai, China. Tianjin Tianyao Pharmaceuticals Co.,Ltd. (stock code: 600488, hereinafter referred to as "Tianjin Tianyao Pharmaceuticals"), as the world's leading manufacturer of steroid hormones and amino acid APIs, attended the Shanghai Exhibition. Zhou Jun, President of Shanghai Industry (Group) Co., Ltd., Chen Jinzhu, Chairman of Tianjin Pharmaceutical Holdings Co., Ltd., Zhang Mingrui, President of Tianjin Pharmaceutical Group, Xu Xiaoyang, Chief Strategy Officer, Li Shuxiang, General Manager of Tianjin Pharmaceutical Group Co., Ltd. and other leaders visited the booth to guide the work, and Liu Xin, Acting Chairman and General Manager of Tianjin Tianyao Pharmaceuticals Co.,Ltd. led the group of people to visist the exhibition.

As a grand event in the field of international pharmaceutical APIs, CPHI Exhibition attracted industry leaders, experts, scholars and business representatives from all over the world. This exhibition gathered all kinds of innovative pharmaceutical products and technologies, providing a platform for exchanges and cooperation and promoting the progress of the pharmaceutical industry.

Highlights in the booth of Tianjin Tianyao Pharmaceuticals Co.,Ltd. include its newly developed high-quality pharmaceutical APIs and its breakthrough in technological innovation. The company's marketing team, together with the production, quality and legal teams, actively participated in the communication with global business partners and conducted in-depth discussions on cooperation opportunities. They showed their professional knowledge and rich experience in the field of pharmaceutical APIs, and won the appreciation and attention of many visitors.

During the exhibition, more than 400 new and old customers came to the company booth for business discussion, understanding and broadening business channels and explored many new cooperation opportunities. Through this exhibition, Tianjin Tianyao Pharmaceuticals Co.,Ltd. reached cooperation intentions with many multinational companies such as PFIZER for the second half of the year, and discussed the development of emerging markets with many foreign partners such as IMCD and RUMIT.

In the future, Tianjin Tianyao Pharmaceuticals Co.,Ltd. will be committed to providing high-quality pharmaceutical APIs products to meet the demands of the global market. Through strict quality control and continuous R&D investment, the company continuously improves the safety and effectiveness of products. The company will work with global business partners to seek cooperation opportunities and common development ways, accelerate the pace of international market development, and further improve brand influence and market competitiveness in the field of steroid and amino acid APIs.